OBJECTIVE: HIV enters the brain soon after infection causing neuronal damage and microglial/astrocyte dysfunction leading to neuropsychological impairment. We examined the impact of HIV on resting cerebral blood flow (rCBF) within the lenticular nuclei (LN) and visual cortex (VC). METHODS: This cross-sectional study used arterial spin labeling MRI (ASL-MRI) to measure rCBF within 33 HIV+ and 26 HIV- subjects. Nonparametric Wilcoxon rank sum test assessed rCBF differences due to HIV serostatus. Classification and regression tree (CART) analysis determined optimal rCBF cutoffs for differentiating HIV serostatus. The effects of neuropsychological impairment and infection duration on rCBF were evaluated. RESULTS: rCBF within the LN and VC were significantly reduced for HIV+ compared to HIV- subjects. A 2-tiered CART approach using either LN rCBF < or =50.09 mL/100 mL/min or LN rCBF >50.09 mL/100 mL/min but VC rCBF < or =37.05 mL/100 mL/min yielded an 88% (29/33) sensitivity and an 88% (23/26) specificity for differentiating by HIV serostatus. HIV+ subjects, including neuropsychologically unimpaired, had reduced rCBF within the LN (p = 0.02) and VC (p = 0.001) compared to HIV- controls. A temporal progression of brain involvement occurred with LN rCBF significantly reduced for both acute/early (<1 year of seroconversion) and chronic HIV-infected subjects, whereas rCBF in the VC was diminished for only chronic HIV-infected subjects. CONCLUSION: Resting cerebral blood flow (rCBF) using arterial spin labeling MRI has the potential to be a noninvasive neuroimaging biomarker for assessing HIV in the brain. rCBF reductions that occur soon after seroconversion possibly reflect neuronal or vascular injury among HIV+ individuals not yet expressing neuropsychological impairment.
OBJECTIVE: HIV enters the brain soon after infection causing neuronal damage and microglial/astrocyte dysfunction leading to neuropsychological impairment. We examined the impact of HIV on resting cerebral blood flow (rCBF) within the lenticular nuclei (LN) and visual cortex (VC). METHODS: This cross-sectional study used arterial spin labeling MRI (ASL-MRI) to measure rCBF within 33 HIV+ and 26 HIV- subjects. Nonparametric Wilcoxon rank sum test assessed rCBF differences due to HIV serostatus. Classification and regression tree (CART) analysis determined optimal rCBF cutoffs for differentiating HIV serostatus. The effects of neuropsychological impairment and infection duration on rCBF were evaluated. RESULTS:rCBF within the LN and VC were significantly reduced for HIV+ compared to HIV- subjects. A 2-tiered CART approach using either LN rCBF < or =50.09 mL/100 mL/min or LN rCBF >50.09 mL/100 mL/min but VC rCBF < or =37.05 mL/100 mL/min yielded an 88% (29/33) sensitivity and an 88% (23/26) specificity for differentiating by HIV serostatus. HIV+ subjects, including neuropsychologically unimpaired, had reduced rCBF within the LN (p = 0.02) and VC (p = 0.001) compared to HIV- controls. A temporal progression of brain involvement occurred with LN rCBF significantly reduced for both acute/early (<1 year of seroconversion) and chronic HIV-infected subjects, whereas rCBF in the VC was diminished for only chronic HIV-infected subjects. CONCLUSION: Resting cerebral blood flow (rCBF) using arterial spin labeling MRI has the potential to be a noninvasive neuroimaging biomarker for assessing HIV in the brain. rCBF reductions that occur soon after seroconversion possibly reflect neuronal or vascular injury among HIV+ individuals not yet expressing neuropsychological impairment.
Authors: A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: C A Wiley; C L Achim; C Christopherson; Y Kidane; S Kwok; E Masliah; J Mellors; L Radhakrishnan; G Wang; V Soontornniyomkij Journal: AIDS Date: 1999-10-22 Impact factor: 4.177
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Lynn M Wachtman; Richard L Skolasky; Patrick M Tarwater; Deneen Esposito; Giovanni Schifitto; Karen Marder; Michael P McDermott; Bruce A Cohen; Avindra Nath; Ned Sacktor; Leon G Epstein; Joseph L Mankowski; Justin C McArthur Journal: Arch Neurol Date: 2007-09
Authors: James T Becker; Melissa Fabrizio; Gustavo Sudre; Anna Haridis; Timothy Ambrose; Howard J Aizenstein; William Eddy; Oscar L Lopez; David A Wolk; Lauri Parkkonen; Anto Bagic Journal: J Neurosci Methods Date: 2012-03-05 Impact factor: 2.390
Authors: Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Margaret R Lentz; Woong-Ki Kim; Hyun Kim; Caroline Soulas; Vallent Lee; Nagagopal Venna; Elkan F Halpern; Eric S Rosenberg; Kenneth Williams; R G González Journal: J Neurovirol Date: 2011-04-15 Impact factor: 2.643
Authors: Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich Journal: Neurology Date: 2014-09-26 Impact factor: 9.910
Authors: Erica Weber; Erin E Morgan; Jennifer E Iudicello; Kaitlin Blackstone; Igor Grant; Ronald J Ellis; Scott L Letendre; Susan Little; Sheldon Morris; Davey M Smith; David J Moore; Steven Paul Woods Journal: J Neurovirol Date: 2012-12-19 Impact factor: 2.643